MissionIRNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Eyes ‘Tip of the Iceberg’ Opportunity with Launch of Platinum Vape(TM) Live Resin in Michigan

 Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a multistate cannabis operator and house of premium brands, together with its RWB Michigan LLC wholly owned subsidiary, today announced the debut of Platinum Vape(TM) (“PV”) Live Resin in Michigan. Previously available only in California and Oklahoma, PV Live Resin will soon be in the nearly 400 Michigan dispensaries that now carry Platinum products. “As promised, the Red White & Bloom team is introducing a steady stream of new products and consumption options to satisfy consumer demand in the rapidly growing Michigan cannabis market,” said Brad Rogers, Red White & Bloom chairman and CEO. “In the U.S., live resin sales grew 86% since 2020, as reported by Greentank*. We believe this is just the tip of the iceberg for the live resin opportunity, since so many new cannabis consumers are totally unfamiliar with live resin and migrate to it once they learn more about cannabis and discover live resins’ many advantages.”

To view the full press release, visit https://ibn.fm/0VqVg

About Red White & Bloom Brands Inc.

Red White & Bloom is a multistate cannabis operator and house of premium brands in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets, including Arizona, California, Florida, Illinois, Oklahoma, and Michigan with respect to cannabis, and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.

*Green Tank North American Vape Market 2021 Year in Review https://www.greentanktech.com/offer/industry-vape-report-2021/

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Inks Retail Partnership with BESTIES Vegan Paradise to Strengthen its Retail Footprint and Product Offering

 

• The partnership will see the rebranding of XMarket brick-and-mortar stores in Venice, and Hillcrest, California, under the BESTIES brand
• PlantX is confident that its partnership with BESTIES will accelerate the already significant growth for PlantX
• In the first month of the rebrand, PlantX posted a 30% growth in sales revenue

Over the past year, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has embarked on an aggressive expansion campaign to strengthen its retail footprint and bring its products and services closer to consumers. This has seen the opening of various XMarket brick-and-mortar stores in strategic locations, the launch of shop-in-shops within Hudson’s Bay locations, and the acquisition of key brands in the vegan space.

In a move that seeks to strengthen its presence in this industry further, PlantX has just announced its retail partnership with BESTIES Vegan Paradise. BESTIES is a leading enterprise in the plant-based space, providing a platform for independent, vegan businesses to contribute to expanding the vegan community (https://ibn.fm/yX9aU).

Launched in 2019 by Asia Phoenix and Matt Fontana, BESTIES has grown into one of the key movers in the plant-based space. Through its innovation and its push to enable a plant-based lifestyle among consumers, it has been awarded “Best Grocery Store” in the VegNews Veggie Awards for two consecutive years. PlantX is confident that this partnership will further both companies’ goals to propel plant-based accessibility for all.

“Both PlantX and I, personally, are committed to the values and ethics that Asia, Matt, and the BESTIES brand have come to epitomize in the vegan community,” noted Sean Dollinger, the Founder of PlantX.

“This partnership will no doubt accelerate the already massive growth for PlantX as we confirm our commitment to those values and cement our place as a leader in the ethical vegan marketplace,” he added.

This collaboration with BESTIES has seen PlantX begin redesigning and rebranding its XMarket brick-and-mortar stores in Venice, California, and Hillcrest, California, under the BESTIES brand. In addition, these locations will stock BESTIES branded products such as vegan soft serve. They will also allow orders placed on its e-commerce stores, with same-day deliveries across Los Angeles and San Diego.

“We are very thankful to be working so closely with the founders of BESTIES, Matt Fontana and Asia Phoenix, who recognize PlantX as a leader in the vegan space,” said Lorne Rapkin, the Chief Executive officer (“CEO”) of PlantX.

“With the knowledge that they too, are industry leaders and want to join forces to roll out their brand with our support is very powerful,” he added.

Following this partnership, PlantX has reported an additional 30% in sales revenue for the first month since the Venice location was rebranded to reflect the BESTIES model. In addition, the company’s management is confident that sales will continue increasing, having tapped into a more recognized brand in the plant-based space.

For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reiterates Commitment to Operational Excellence, Advancing Berubicin Recognition

 

• In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuations
• CNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiforme
• Interim analysis of the trial is currently expected as early as the first quarter of 2023, once 30-50% of trial patients have been on the study for six months

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system, has released a video to its shareholders that reiterates the operational and clinical progress of its lead drug candidate, Berubicin. The video features CNS CEO John Climaco and addresses the recent share price activity (https://ibn.fm/Z40Gw).

“The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market – both of which are things out of our control,” Climaco said in his video message. “However, as the CEO, what I do have control over is executing on the day-to-day operations, which I want to reiterate and emphasize have simply never been stronger.”

Climaco went on to detail the company’s operational strengths, including the fact that it continues to enroll patients in its potentially pivotal global study of Berubicin in the treatment of adult glioblastoma multiforme (“GBM”). “We have the leading minds in the field around the world working on this trial with us, and we have encouraging ongoing dialogue with the FDA to ensure that our potentially pivotal trial continues to represent the state-of-the-art in the field,” he said.

The CNS CEO also underlined that his company remains committed to continuing to execute its operational excellence to drive recognition in the market of Berubicin and its immense potential for patients – the key driver for ultimately generating shareholder value and tremendous hope for GBM patients worldwide. “We put our heads down every day and continue to charge forward in our mission to change the game in glioblastoma via Berubicin,” Climaco added.

The video comes days after the company released its full-year 2021 financial results and corporate update, highlighting key milestones during the previous year, including (https://ibn.fm/Lb1r3):

• May 2021 – Beginning of patient enrollment for a potentially pivotal global study evaluating the efficacy of Berubicin for adult recurring GBM
• June 2021 – Granting of Fast Track Designation by the FDA for recurrent GBM treatment with Berubicin
• September 2021 – First patients from potentially pivotal study dosed with Berubicin
• December 2021 – Approval from “swissethics,” the umbrella organization of the Ethics Committee (“EC”) in Switzerland, for the potentially pivotal study of Berubicin for treatment of recurrent GBM to proceed in Switzerland
• January 2022 – Announcement of $11.5 million private placement, priced at the market under NASDAQ rules

CNS plans to expand the potentially pivotal study of Berubicin in recurrent GBM into additional countries and complete the enrollment needed for the interim analysis of the study within the year. The interim analysis of the trial will occur when 30-50% of the total expected patients have been on the study for at least six months, which is anticipated during the first half of 2023.

Berubicin is a novel anthracycline and the first that appears to cross the blood-brain barrier. It is currently in development for the treatment of a number of serious brain and oncology indications. The first trial of the drug was initiated by Reata Pharmaceuticals over 16 years ago. It resulted in one patient surviving cancer-free, and two others reporting a reduction in tumor size of up to 80%.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 24th Patent Sets the Stage for New Market Opportunities in Australia

 Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, celebrated the receipt of its 24th granted patent entitled “Compositions Infused with Nicotine Compounds and Methods of Use Thereof.” Granted in Australia, this is the first patent awarded from the company’s 8th patent family. “The new patent expands on the company’s international IP rights to apply DehydraTECH(TM) technology to most forms of nicotine, namely sprays, gums, lozenges, pouches, capsules, tablets, and pills. It also covers multiple disparate forms of nicotine, including polymer resins of nicotine, freebase nicotine and other nicotine complexes,” reads a recent article. Prior to the award of the 24th patent, Lexaria already had a patent granted in Australia to use DehydraTECH-processed cannabidiol (“CBD”) to potentially treat heart disease. “Thus, the new Australian patent covering the use of DehydraTECH-nicotine builds on the existing IP protection there and sets the stage for the company to exploit nicotine- and CBD-oriented opportunities within this market.”

To view the full article, visit https://ibn.fm/57T9I

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Knightscope Inc. (NASDAQ: KSCP) Releases Spring 2022 Robot Roadshow Schedule

 Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced its spring 2022 Robot Roadshow schedule. Designed to be an engaging experiential event that allows Knightscope to connect with potential clients and showcase its proprietary crime-fighting robots, the Robot Roadshow will begin on April 12, 2022, and will tour 10 states, including Minnesota, Wisconsin, Illinois, Indiana and Ohio, with 35 scheduled stops. The roadshow will also be in Washington, D.C. during National Police Week. Creative marketing events such as the Robot Roadshow allow KSCP, a public safety innovator, to educate existing and potential clients and others about its Autonomous Security Robots (“ASRs”). Each roadshow landing is attended virtually by a Knightscope expert, and visitors can interact directly with ASRs as well as view the Knightscope Security Operations Center (“KSOC”) user interface in action. Knightscope is planning to continue the Robot Roadshow throughout the year, hitting as many major cities as possible.

To view the full press release, visit https://ibn.fm/YHFDe

About Knightscope Inc.

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knight are available in the company’s newsroom at https://ibn.fm/Knight

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Flora Growth Corp.’s (NASDAQ: FLGC) CEO Slated to Present Keynote at Upcoming Plant Medicine Week Conference

 Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, will be participating in the Plant Medicine Week conference, which is scheduled to be held April 5–8, 2022, in Malta. Flora Growth chair and CEO Luis Merchan is the keynote speaker at the four-day event. Merchan’s presentation, titled “Malta — The Gateway to South American and European Cannabis Relations,” is slated to start at 2:30 CET and will focus on the opportunity presented by Malta’s standpoint on cannabis as well as the cost advantages of South American cultivation and the broader European opportunity. The Plant Medicine Week conference in Malta is designed to gather together industry professionals and attendees and provide them with a diverse and inspiring perspective on the latest advances in the cannabis and psychedelics industries; the event agenda features a mix of exhibitions, presentations, discussions and Q&A sessions. In addition to delivering the keynote address, Merchan will be available for meetings with interested media and others who may want to hear about the cannabis opportunity in the European Union, the industry’s need for more sustainable cultivation practices and Flora’s growth strategy. “I’m honored to be keynote speaker at the Plant Medicine Week conference this year in Malta,” said Flora Growth CEO Luis Merchan in the press release. “I look forward to sharing our expertise as a global cultivator and distributor in the international cannabis space and continuing to foster our relationship with the country of Malta, a leader in Europe’s cannabis trade.”

To view the full press release, visit https://ibn.fm/5r1oT  

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html